Heart failure
Drug research and approvals for heart failure: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,022 studies of heart failure are recruiting on ClinicalTrials.gov, Health Canada has authorized 101 drug trials for it since 2013, FDA has 1 approved and 3 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 1,022
- Trials authorized in Canada: 101
- FDA orphan approvals: 1
- EU medicines: 6
- Multimodal Assessment of Remodeling and Stratification in Heart FailureNCT07940868 · Not reported · Shandong Provincial Hospital · starts Dec 1, 2022
- Effects of Primary Physician Presence in AI-Synthesized SGLT2 Inhibitor Educational Videos for Heart FailureNCT07937540 · Not applicable · Keimyung University Dongsan Medical Center · starts Aug 21, 2026
- Remote Rehabilitation in Patients With HFpEF (PATRON-HF)NCT07918209 · Not applicable · American Heart of Poland · starts Sep 30, 2025
- dPmax for Predicting Right Ventricular Failure After Left Ventricular Assist Device ImplantationNCT07918690 · Not reported · Pınar Kırdemir · starts Jun 3, 2026
- Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary ConditionsNCT07915882 · Not applicable · Michael Incze · starts Oct 13, 2026
- 31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease SpectrumNCT07912086 · Not reported · Chinese Academy of Medical Sciences, Fuwai Hospital · starts Aug 1, 2025
- Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac PatientsNCT07913152 · Not applicable · Tel-Aviv Sourasky Medical Center · starts Jun 17, 2026
- Evaluating a Digital Aid to Improve ICD DecisionsNCT07913204 · Not applicable · Stanford University · starts Oct 19, 2026
- Impact of a Tailored Digital Intervention on Sedentary Behaviour and Physical Health in Long-term Cardiac…NCT07910812 · Not applicable · University of Lisbon · starts Oct 1, 2025
Approved 24 of 46
- ValsartanType-1 angiotensin II receptor antagonist
- SacubitrilNeprilysin inhibitor
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- SpironolactoneMineralocorticoid receptor antagonist
- AmlodipineVoltage-gated L-type calcium channel blocker
- EnalaprilAngiotensin-converting enzyme inhibitor
- IvabradinePotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
- CarvedilolAdrenergic receptor beta antagonist
- TolvaptanVasopressin V2 receptor antagonist
- VericiguatSoluble guanylate cyclase activator
- TorsemideSodium-(potassium)-chloride cotransporter 2 inhibitor
- MilrinonePhosphodiesterase 3A inhibitor
- DigoxinSodium/potassium-transporting ATPase inhibitor
- MetolazoneThiazide-sensitive sodium-chloride cotransporter inhibitor
- NitroglycerinSoluble guanylate cyclase activator
- EplerenoneMineralocorticoid receptor antagonist
- LisinoprilAngiotensin-converting enzyme inhibitor
- BumetanideSodium-(potassium)-chloride cotransporter 2 inhibitor
- Candesartan cilexetilType-1 angiotensin II receptor antagonist
- MetoprololBeta-1 adrenergic receptor antagonist
- Olmesartan medoxomilType-1 angiotensin II receptor antagonist
- RamiprilAngiotensin-converting enzyme inhibitor
Phase 3 12 of 57
- LevosimendanPhosphodiesterase 3 inhibitor
- NesiritideAtrial natriuretic peptide receptor A agonist
- Omecamtiv mecarbilCardiac myosin activator
- SerelaxinRelaxin receptor 1 activator
- FinerenoneMineralocorticoid receptor antagonist
- Human neuregulin-1 recombinant (177-237)
- AliskirenRenin inhibitor
- SildenafilPhosphodiesterase 5A inhibitor
- PrednisoneGlucocorticoid receptor agonist
- ColchicineTubulin inhibitor
- SomatropinGrowth hormone receptor agonist
- RosuvastatinHMG-CoA reductase inhibitor
Phase 2 12 of 80
- AnakinraInterleukin-1 receptor antagonist
- Cimlanod
- Cenderitide
- Nitrous acid
- BAY1067197Adenosine A1 receptor agonist
- IstaroximeSodium/potassium-transporting ATPase inhibitor
- Elamipretide
- Mitiperstat
- AllopurinolXanthine dehydrogenase inhibitor
- ErgocalciferolVitamin D receptor agonist
- CinaciguatSoluble guanylate cyclase activator
- Relaxin
Phase 1 or earlier 12 of 36
- BalcinrenoneMineralocorticoid receptor modulator
- ItraconazoleCytochrome P450 51 inhibitor
- BMS-986224
- BosentanEndothelin receptor, ET-A/ET-B antagonist
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- MoxifloxacinTopoisomerase IV inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- GadobutrolDiagnostic agent
- LiothyronineThyroid hormone receptor agonist
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- FenoterolBeta-2 adrenergic receptor agonist
- TadalafilPhosphodiesterase 5A inhibitor
How its trials ended
5,179 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 1,268 whose ending is known, 37% met their primary endpoint, 12% missed it and 52% stopped early.
- Completed, result not reported1,98738%
- Ongoing1,13022%
- Status unknown79415%
- Met its primary endpoint4639%
- Stopped: other or unclear3487%
- Stopped: enrollment or feasibility1693%
- Missed its primary endpoint1503%
- Stopped: sponsor or business decision561%
- Stopped: lack of efficacy391%
- Stopped: funding331%
- Stopped: safety10<1%
| Oct 29, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sotatercept in adults with combined postcapillary and…Winrevair (sotatercept (MK-7962)) | Merck & Co. (MSD) | Pending |
| Jul 13, 2026 | A multicenter, open-label, long-term extension study for oral levosimendan (TNX-103)Levosimendan (TNX-103) | Tenax Therapeutics | Pending |
| Jun 23, 2026 | Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin…AC01 (HM01) | Anacardio AB | Pending |
| May 12, 2026 | A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the effect of elecoglipron in reducing cardiovascular…Elecoglipron (AZD5004) / Dapagliflozin | AstraZeneca Pharmaceuticals | Ongoing |
| Mar 19, 2026 | Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection…NNC0487-0111 | Novo Nordisk | Ongoing |
| Dec 5, 2025 | A multi-center, randomized, participant- and investigator- blinded, placebo-controlled crossover study to investigate the safety, tolerability, and…HJB647 | Novartis Pharmaceuticals | Ongoing |
| Oct 28, 2025 | Oral l-carnitine supplementation in cardiorenal heart failure patientsLevocarnitine | London Health Sciences Centre | Ongoing |
| Aug 29, 2025 | A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to investigate the efficacy, safety, and pk/ pd of finerenone, in addition to…Finerenone (bay 94-8862) | Bayer | Ongoing |
| Aug 29, 2025 | A phase 3, single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard of care, in pediatric heart failure patients,…Finerenone (bay 94-8862) | Bayer | Ongoing |
| Jun 25, 2025 | A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of maridebart cafraglutide on mortality and morbidity in…Maridebart cafraglutide (amg 133) | Amgen | Ongoing |
| Apr 22, 2019 | CorlanorCorlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged… | Amgen, Inc., | Approved |
| Jan 8, 2018 | MilrinoneTreatment of right heart failure (RHF) in left ventricular assist device (LVAD) patients | Hyloris Developments SA | Designated |
| Nov 2, 2004 | Sitaxsentan SodiumFor the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure. | Pfizer Global Research and Development | Designated |
| Apr 12, 2004 | Ubiquinol, coenzyme Q10, ubiquinoneTreatment of pediatric congestive heart failure | Gel-Tec, Division of Tishcon Corporation | Designated |
| Nov 15, 2023 | AqumeldiEnalapril maleate | Proveca Pharma Limited | EMA ↗ |
| Jul 16, 2021 | VerquvoVericiguat | Bayer AG | EMA ↗ |
| Apr 19, 2017 | RoteasEdoxaban | Berlin-Chemie AG | EMA ↗ |
| May 26, 2016 | NeparvisSacubitril; valsartan | Novartis Europharm Limited | EMA ↗ |
| Nov 19, 2015 | EntrestoSacubitril; valsartan | Novartis Europharm Limited | EMA ↗ |
| Jun 19, 2015 | LixianaEdoxaban | Daiichi Sankyo Europe GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA